Evidence map›Paper›PMID 40133484›Full record

ArticleNPJ precision oncology2025

ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial.

Thomas J Herzog, Thomas C Krivak, Stephen Bush, John P Diaz, Scott Lentz, Navya Nair, Nadim Bou Zgheib, Camille Gunderson-Jackson, Abhijit Barve, Krista L Denning and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03949283 (Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03949283 phase3active not recruitingnot on this map

Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

TypeinterventionalSponsorCordgenics, LLCRan2019 to 2024Enrolled150ConditionsRecurrent Ovarian Carcinoma, Platinum-resistant Ovarian CancerArmsChemoID Assay, Standard Chemotherapy
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Thomas J HerzogDepartment of Obstetrics and Gynecology, University of Cincinnati Cancer Center, Cincinnati, USA.
Thomas C KrivakDivision of Gynecologic Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, USA.
Stephen BushDepartment of Obstetrics and Gynecology, Charleston Area Medical Center Vandalia Health, Charleston, USA.
John P DiazGynecologic Oncology, Baptist Health South Florida, Miami Cancer Institute, Miami, USA.
Scott LentzGynecology Oncology Department, Kaiser Permanente Los Angeles Medical Center, Los Angeles, USA.
Navya NairDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, Louisiana State University, New Orleans, USA.
Nadim Bou ZgheibEdwards Comprehensive Cancer Center, Joan C. Edwards School of Medicine, Marshall University, Huntington, USA.
Camille Gunderson-JacksonDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
Abhijit BarveClinical Development & Medical Affairs, Viatris Inc, Canonsburg, USA.
Krista L DenningDepartment of Pathology, Joan C. Edwards School of Medicine, Marshall University, Huntington, USA.
Seth T LiretteDepartment of Data Science, University of Mississippi Medical Center, Translational Research Center, Jackson, USA.
Candace M HowardDepartment of Radiology, University of Mississippi Medical Center, Jackson, USA.
Jagan ValluriCordgenics, LLC, Huntington, USA.
Pier Paolo ClaudioCordgenics, LLC, Huntington, USA. pclaudio@umc.edu.ORCID http://orcid.org/0000-0001-7790-1622

Funding

Tracking and Evaluation CoreU54GM115428 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI COMPRETTA, CAROLINE E. · 2016 to 2025
$38.2M
Role of obesity in preeclamptic pregnancy.P20GM121334 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI Babbette LaMarca, Jane F Reckelhoff · 2017 to 2026
$26.4M
NIGMS NIH HHS P20 GM121334NIGMS NIH HHS U54 GM115428
6 · The paper itself

Abstract

Patients with recurrent platinum-resistant ovarian cancer (PROC) have poor clinical outcomes, owing mainly to the presence of therapy-resistant cancer stem cells (CSCs). The NCT03949283 randomized clinical trial enrolled patients with recurrent PROC to receive ChemoID-guided chemotherapy or the best physician-choice regimen selected from the same list of thirteen mono or combination chemotherapies. The primary outcome was objective response rate (ORR) assessed on CT scans using the RECIST 1.1 criteria at 6 months follow-up. Subjects treated with the ChemoID assay had an ORR of 55% (CI

Identifiers

PMID40133484
PMCPMC11937309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.